An independent data monitoring committee has advised Akeso to submit a sNDA to the NMPA for cadonilimab’s approval in gastric ...

KYOTO--Researchers at Kyoto University have identified a new approach to a type of colorectal cancer that is resistant to ...

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...

US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while ...

Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer ...

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

The court directed Zydus to maintain detailed and audited records of its sales during this period so that the innovator can ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the cheap stocks to buy for the next 3 years. On January 9, Scotiabank ...

Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or ...

Ultimo Moné lost her second championship in the month of December, and Kevin Knight pulled off a massive upset in the Continental Classic. Here are all the results and highlights from AEW Collision ...

Bristol Myers Squibb and its subsidiary Karuna Therapeutics received the latest Untitled Letter from the Food and Drug Administration earlier this week. In a letter issued on December 15 to Nicole Van ...

Ontario becomes the first province to list the combination under the new FAST pilot program, supporting timely access for eligible patients "For thousands of Ontarians facing a cancer diagnosis, fast ...